R. Stupp, M. E. Hegi, W. P. Mason, M. J. Van-den-bent, M. Taphoorn et al., Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial, Lancet Oncol, vol.10, issue.5, pp.459-66, 2009.

A. Olar and K. D. Aldape, Using the molecular classification of glioblastoma to inform personalized treatment, J Pathol, vol.232, issue.2, pp.165-77, 2014.

H. S. Phillips, S. Kharbanda, R. Chen, W. F. Forrest, R. H. Soriano et al., Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis, Cancer Cell, vol.9, issue.3, pp.157-73, 2006.

R. Verhaak, K. A. Hoadley, E. Purdom, V. Wang, Y. Qi et al., Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1, Cancer Cell, vol.17, issue.1, pp.98-110, 2010.

Q. Wang, B. Hu, X. Hu, H. Kim, M. Squatrito et al., Tumor evolution of glioma intrinsic gene expression subtype associates with immunological changes in the microenvironment, Cancer Cell, vol.32, issue.1, pp.42-56, 2017.

C. Pecqueur, L. Oliver, K. Oizel, L. Lalier, and F. M. Vallette, Targeting metabolism to induce cell death in cancer cells and cancer stem cells, Int J Cell Biol, vol.2013, pp.1-13, 2013.
URL : https://hal.archives-ouvertes.fr/inserm-02447021

H. Clevers, The cancer stem cell: premises, promises and challenges, Nat Med, vol.17, issue.3, pp.313-322, 2011.

J. P. Medema, Cancer stem cells: the challenges ahead, Nat Cell Biol, vol.15, issue.4, pp.338-382, 2013.

K. Oizel, C. Chauvin, L. Oliver, C. Gratas, F. Geraldo et al., Efficient mitochondrial glutamine targeting prevails over glioblastoma metabolic plasticity, Clin Cancer Res Off J Am Assoc Cancer Res, vol.23, issue.20, pp.6292-304, 2017.
URL : https://hal.archives-ouvertes.fr/inserm-01595798

I. Marin-valencia, C. Yang, T. Mashimo, S. Cho, H. Baek et al., Analysis of tumor metabolism reveals mitochondrial glucose oxidation in genetically diverse human glioblastomas in the mouse brain in vivo, Cell Metab, vol.15, issue.6, pp.827-864, 2012.

A. A. Sergushichev, An algorithm for fast preranked gene set enrichment analysis using cumulative statistic calculation, p.60012, 2016.

K. Oizel, C. Gratas, A. Nadaradjane, L. Oliver, F. M. Vallette et al., D-2-Hydroxyglutarate does not mimic all the IDH mutation effects, in particular the reduced etoposide-triggered apoptosis mediated by an alteration in mitochondrial NADH, Cell Death Dis, vol.6, p.1704, 2015.
URL : https://hal.archives-ouvertes.fr/inserm-01818661

M. Yuan, S. B. Breitkopf, X. Yang, and J. M. Asara, A positive/negative ion-switching, targeted mass spectrometry-based metabolomics platform for bodily fluids, cells, and fresh and fixed tissue, Nat Protoc, vol.7, issue.5, pp.872-81, 2012.

S. Tardito, A. Oudin, S. U. Ahmed, F. Fack, O. Keunen et al., Glutamine synthetase activity fuels nucleotide biosynthesis and supports growth of glutamine-restricted glioblastoma, Nat Cell Biol, vol.17, issue.12, pp.1556-68, 2015.

P. Caro, A. U. Kishan, E. Norberg, I. A. Stanley, B. Chapuy et al., Metabolic signatures uncover distinct targets in molecular subsets of diffuse large B cell lymphoma, Cancer Cell, vol.22, issue.4, pp.547-60, 2012.

S. Venneti, M. P. Dunphy, H. Zhang, K. L. Pitter, P. Zanzonico et al., Glutamine-based PET imaging facilitates enhanced metabolic evaluation of gliomas in vivo, Sci Transl Med, vol.7, issue.274, pp.274-291, 2015.

M. A. Gregory, T. Nemkov, H. J. Park, V. Zaberezhnyy, S. Gehrke et al., Targeting glutamine metabolism and redox state for leukemia therapy, Clin Cancer Res Off J Am Assoc Cancer Res, vol.25, issue.13, pp.4079-90, 2019.

J. Wang, J. W. Erickson, R. Fuji, S. Ramachandran, P. Gao et al., Targeting mitochondrial glutaminase activity inhibits oncogenic transformation, Cancer Cell, vol.18, issue.3, pp.207-226, 2010.

M. I. Gross, S. D. Demo, J. B. Dennison, L. Chen, T. Chernov-rogan et al., Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer, Mol Cancer Ther, vol.13, issue.4, pp.890-901, 2014.

M. J. Seltzer, B. D. Bennett, A. D. Joshi, P. Gao, A. G. Thomas et al., Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1, Cancer Res, vol.70, issue.22, pp.8981-8988, 2010.

C. M. Metallo, P. A. Gameiro, E. L. Bell, K. R. Mattaini, J. Yang et al., Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia, Nature, 2011.

A. Muir, L. V. Danai, D. Y. Gui, C. Y. Waingarten, and C. A. Lewis, Vander Heiden MG. Environmental cystine drives glutamine anaplerosis and sensitizes cancer cells to glutaminase inhibition, vol.15, p.6, 2017.

M. Reina-campos, J. Moscat, and M. Diaz-meco, Metabolism shapes the tumor microenvironment, Curr Opin Cell Biol, vol.48, pp.47-53, 2017.

S. M. Davidson, T. Papagiannakopoulos, B. A. Olenchock, J. E. Heyman, M. A. Keibler et al., Environment impacts the metabolic dependencies of Ras-driven non-small cell lung cancer, Cell Metab, vol.23, issue.3, pp.517-545, 2016.

A. Kinnaird, S. Zhao, K. E. Wellen, and E. D. Michelakis, Metabolic control of epigenetics in cancer, Nat Rev Cancer, vol.16, issue.11, pp.694-707, 2016.

M. E. Hegi, L. Liu, J. G. Herman, R. Stupp, W. Wick et al., Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity, J Clin Oncol Off J Am Soc Clin Oncol, vol.26, issue.25, pp.4189-99, 2008.

A. Lai, A. Tran, P. L. Nghiemphu, W. B. Pope, O. E. Solis et al., Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme, J Clin Oncol Off J Am Soc Clin Oncol, vol.29, issue.2, pp.142-150, 2011.

H. S. Friedman, M. D. Prados, P. Y. Wen, T. Mikkelsen, D. Schiff et al., Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma, J Clin Oncol Off J Am Soc Clin Oncol, vol.27, issue.28, pp.4733-4773, 2009.

X. Jin, L. Kim, Q. Wu, L. C. Wallace, B. C. Prager et al., Targeting glioma stem cells through combined BMI1 and EZH2 inhibition, Nat Med, vol.23, issue.11, pp.1352-61, 2017.

K. Garber, Cancer anabolic metabolism inhibitors move into clinic, Nat Biotechnol, vol.34, issue.8, pp.794-799, 2016.

C. Corbet, E. Bastien, N. Draoui, B. Doix, L. Mignion et al., Interruption of lactate uptake by inhibiting mitochondrial pyruvate transport unravels direct antitumor and radiosensitizing effects, Nat Commun, vol.9, issue.1, p.1208, 2018.

M. Morfouace, L. Lalier, L. Oliver, M. Cheray, C. Pecqueur et al., Control of glioma cell death and differentiation by PKM2-Oct4 interaction, Cell Death Dis, vol.5, p.1036, 2014.